Shaping Antitumor Immunity with Peptide Vaccines: Implications of Immune Modulation at the Vaccine Site

Cancer vaccines have emerged as a class of therapeutics designed to harness the immune system to stimulate durable anti-tumor responses with lower systemic toxicity than conventional therapies. Many platforms have been explored, including protein, peptide, DNA, RNA, and cell-based vaccines. Within this landscape, peptide vaccines remain a promising approach. Most clinical trials have examined peripheral immune responses and clinical outcomes, but there is growing interest in the vaccine site microenvironment (VSME) as a window to understand local immune activation and its implications for systemic immunity and tumor control. Studies of the VSME have investigated the effects of adjuvants, local immune cell dynamics, and their correlation with systemic responses and outcomes. Local adjuvants typically enhance immune cell infiltration, though there are concerns regarding VSME sequestration or dysfunction of immune cells, which could impact systemic efficacy. Repeated vaccination at a single site may improve antigen presentation and immune responses, but factors such as injection site location may be linked to variability in clinical outcomes. Current studies are limited by substantial variability in sampling, timing, and analyses used in VSME assessment. This limits the comparability of findings and broader inferences regarding the influence of vaccine site dynamics on therapeutic efficacy. Standardized VSME assessment as part of future vaccine trials may improve evaluation of immune responses and provide a more consistent surrogate for vaccine effectiveness. This refinement may inform optimal vaccine strategies and further support the development of next-generation cancer immunotherapies.

• Publication year

  2025

• Venue

  Vaccines

• Publication date

  2025-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/vaccines13111150PMID 41295524PMCID 12656943
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advancement insights in cancer vaccines: mechanisms, types, and clinical applications

  2025cited by this paper
• Advancements in single-cell RNA sequencing and spatial transcriptomics: transforming biomedical research

  2025cited by this paper
• Cancer Vaccines: Methods and Protocols

  2025cited by this paper
• A neoantigen vaccine generates antitumour immunity in renal cell carcinoma

  2025cited by this paper
• The Application of Single-Cell Technologies for Vaccine Development Against Viral Infections

  2025cited by this paper
• Recent advances in therapeutic cancer vaccines

  2025cited by this paper
• Current Landscape of Therapeutic Cancer Vaccines.

  2025cited by this paper
• Tertiary Lymphoid Structures as a Biomarker in Immunotherapy and Beyond: Advancing Towards Clinical Application.

  2025cited by this paper
• Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches

  2025cited by this paper
• Single-cell spatial transcriptomics unravels cell states and ecosystems associated with clinical response to immunotherapy

  2025cited by this paper
• Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site

  2025cited by this paper
• Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis

  2024cited by this paper
• Cancer statistics, 2024

  2024cited by this paper
• Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones

  2024cited by this paper
• Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.

  2024cited by this paper
• iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens

  2024cited by this paper
• Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.

  2024cited by this paper
• Cancer mRNA vaccines: clinical advances and future opportunities

  2024cited by this paper
• IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines

  2024cited by this paper
• Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis

  2024cited by this paper
• Stability of Multi-Peptide Vaccines in Conditions Enabling Accessibility in Limited Resource Settings

  2024cited by this paper
• mRNA vaccine trafficking and resulting protein expression after intramuscular administration

  2023cited by this paper
• Immune checkpoint therapy-current perspectives and future directions.

  2023cited by this paper
• Spatial Transcriptomics: Emerging Technologies in Tissue Gene Expression Profiling

  2023cited by this paper
• Sources of Cancer Neoantigens beyond Single-Nucleotide Variants

  2022cited by this paper
• The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling

  2022influential reference
• Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer: A Review.

  2022cited by this paper
• Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions

  2022cited by this paper
• Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

  2022cited by this paper
• Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer

  2022cited by this paper
• Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials

  2022cited by this paper
• Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials

  2021influential reference
• Single-Cell Analysis of Antigen-Specific CD8+ T-Cell Transcripts Reveals Profiles Specific to mRNA or Adjuvanted Protein Vaccines

  2021cited by this paper
• Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma

  2021cited by this paper
• Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics

  2021cited by this paper
• Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies

  2021cited by this paper
• RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy

  2021cited by this paper
• Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells

  2021cited by this paper
• Emerging technologies for systems vaccinology - multi-omics integration and single-cell (epi)genomic profiling.

  2020cited by this paper
• Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration

  2020cited by this paper
• Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

  2020cited by this paper
• Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study

  2020cited by this paper
• Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors

  2020cited by this paper
• Tertiary lymphoid structures in the era of cancer immunotherapy

  2019cited by this paper
• A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

  2019cited by this paper
• A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

  2019cited by this paper
• Aspects of intradermal immunization with different adjuvants: The role of dendritic cells and Th1/Th2 response

  2019cited by this paper
• Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

  2018cited by this paper
• Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication

  2018cited by this paper
• Long‐term regulation of local cytokine production following immunization in mice

  2018cited by this paper
• Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma

  2018cited by this paper
• Trial watch: Peptide-based vaccines in anticancer therapy

  2018cited by this paper
• Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy

  2017cited by this paper
• Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake

  2017cited by this paper
• Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8+ T Cell Responses

  2017cited by this paper
• Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

  2017cited by this paper
• Cellular Mucins: Targets for Immunotherapy.

  2017cited by this paper
• Measuring the Adjuvant Activity of RNA Vaccines.

  2017cited by this paper
• Tertiary Lymphoid Organs in Cancer Tissues

  2016cited by this paper
• TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients

  2016cited by this paper
• Fine‐needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities

  2016cited by this paper
• High Density of Tumor-infiltrating B-Lymphocytes and Plasma Cells Signifies Prolonged Overall Survival in Adenocarcinoma of the Esophagogastric Junction.

  2016cited by this paper
• Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2016cited by this paper
• Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma

  2015cited by this paper
• A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

  2015cited by this paper
• Cancer vaccines

  2015cited by this paper
• Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma

  2014cited by this paper
• T cells in the human metastatic melanoma microenvironment express site‐specific homing receptors and retention integrins

  2014cited by this paper
• Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

  2014cited by this paper
• Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

  2013cited by this paper
• Vaccine Injection Site Matters: Qualitative and Quantitative Defects in CD8 T Cells Primed as a Function of Proximity to the Tumor in a Murine Glioma Model

  2013cited by this paper
• Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide

  2013influential reference
• Peptide Vaccination in Montanide Adjuvant Induces and GM-CSF Increases CXCR3 and Cutaneous Lymphocyte Antigen Expression by Tumor Antigen–Specific CD8 T Cells

  2013cited by this paper
• Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

  2013cited by this paper
• Examining T Cells at Vaccine Sites of Tumor-bearing Hosts Provides Insights to Dysfunctional T-Cell Immunity

  2013cited by this paper
• The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides

  2012cited by this paper
• Function but not phenotype of melanoma peptide‐specific CD8+ T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696)

  2012cited by this paper
• Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• Viral vector-based therapeutic cancer vaccines.

  2011cited by this paper
• A Comparison of Fine-needle Aspiration, Core Biopsy, and Surgical Biopsy in the Diagnosis of Extremity Soft Tissue Masses

  2010cited by this paper
• Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.

  2010cited by this paper
• Lympho-geographical concepts in vaccine delivery.

  2010cited by this paper
• Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis

  2010cited by this paper
• Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696

  2009cited by this paper
• Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

  2009cited by this paper
• Phenotype and Functional Characterization of Long-term gp100-Specific Memory CD8+ T Cells in Disease-Free Melanoma Patients Before and After Boosting Immunization

  2008cited by this paper
• CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans

  2008cited by this paper
• Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

  2008cited by this paper
• Fine‐needle aspiration cytology of soft tissue lesions: Diagnostic challenges

  2007cited by this paper
• Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma

  2007cited by this paper
• Alum with Interleukin-12 Augments Immunity to a Melanoma Peptide Vaccine: Correlation with Time to Relapse in Patients with Resected High-Risk Disease

  2007cited by this paper
• Melanoma

  2006cited by this paper
• Aluminium compounds for use in vaccines

  2004cited by this paper
• Effects of granulocyte‐macrophage colony‐stimulating factor and foreign helper protein as immunologic adjuvants on the T‐cell response to vaccination with tyrosinase peptides

  2003cited by this paper
• Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

  2002cited by this paper
• Sustained Release of Granulocyte–Macrophage Colony-Stimulating Factor From a Modular Peptide-Based Cancer Vaccine Alters Vaccine Microenvironment and Enhances the Antigen-Specific T-Cell Response

  2001cited by this paper
• Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.

  2001cited by this paper
• Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

  1999cited by this paper
• Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration

  1998cited by this paper

• No citing papers are available for this paper.